at PMDA official site.

Analytical and Clinical Validation for Japan CDx

PMDA requires CDx developers to submit:

• Analytical performance data (LOD, specificity, reproducibility)
• Clinical data supporting the diagnostic-therapeutic linkage
• Design control and manufacturing process validation
• Post-marketing surveillance plans (GVP compliance)

Example values expected by PMDA:

• LOD: 0.05–0.1 ng/mL for protein biomarkers
• Precision: CV ≤10% intra-assay and ≤15% inter-assay
• Agreement with predicate: ≥95%

China: NMPA (formerly CFDA) Companion Diagnostic Pathways

The National Medical Products Administration (NMPA) regulates CDx in China. CDx intended to guide therapy decisions must undergo device registration and be co-approved with the drug.

• Device Type: Class III IVD
• Clinical Evaluation: Local clinical trials typically required
• Submission Dossier: Performance data, labeling, manufacturing, clinical evidence
• Turnaround Time: 18–24 months on average

Notable Guidance: NMPA Technical Guidelines on Companion Diagnostics (2021)

Companies must localize sample testing and ensure full translation of documentation into Mandarin.

South Korea: MFDS IVD Approval System

In South Korea, the Ministry of Food and Drug Safety (MFDS) oversees CDx approval. Classification depends on risk and intended use, with most CDx falling under Class III.

• Clinical Trial Waiver: Possible with adequate bridging data
• Post-Market Surveillance: 4-year re-evaluation period
• Conformity Assessment: MFDS review with GMP certification
• Localization: Translation of IFUs and labeling into Korean

Learn more about MFDS IVD strategy at MFDS website.

Australia and TGA CDx Regulation

Australia’s Therapeutic Goods Administration (TGA) regulates CDx under its medical device framework. Since 2020, companion diagnostics used to guide prescription decisions have been explicitly regulated.

• Device Classification: Class 3 IVD medical device
• Approval Pathways: Conformity assessment certification or mutual recognition (EU/FDA)
• Clinical Evidence: Required to demonstrate therapeutic linkage
• Labeling: Must include drug indication and biomarker relationship

Australia allows fast-track pathways for devices approved by FDA or CE-marked under IVDR.

ASEAN and Singapore HSA Guidelines

In the ASEAN region, Singapore’s Health Sciences Authority (HSA) provides one of the most mature frameworks for CDx. While most other ASEAN countries still rely on CE marking, Singapore requires local evaluation for high-risk IVDs.

• Registration Route: Full evaluation or abridged if approved by HSA reference countries
• CDx Classification: Class C or D based on intended use
• Clinical Evidence: Foreign data accepted with justification
• Labeling: Clear therapeutic product linkage required

ASEAN Medical Device Directive (AMDD) implementation is in progress across Indonesia, Malaysia, Thailand, and Vietnam.

Bridging Studies: Local Data Expectations Across APAC

Japan and China often require bridging studies to validate clinical trial data from Western populations. Elements include:

• Ethnic sensitivity analysis
• Subset testing of local patient samples
• Statistical agreement between global and local data

Regulators may allow retrospective studies using banked samples from Asian patients if prospective studies are not feasible.

Global CDx Co-Development Strategy: APAC Integration

To align CDx development across the US, EU, and APAC regions, developers should:

• Start PMDA consultations in parallel with FDA Q-subs
• Pre-validate test kits with regional labs (Japan, China)
• Use harmonized protocols for analytical validation
• Plan separate regulatory dossiers for each country

Reference guidance from PharmaValidation.in for bridging strategy templates.

Case Study: EGFR CDx Across APAC Markets

An EGFR mutation detection CDx was developed for NSCLC across Japan, China, and Australia. Regulatory milestones included:

• Japan: PMDA approval based on bridging study and local site validation
• China: Full NMPA registration with local patient trial data
• Australia: CE mark recognition with fast-track TGA listing

Result: Simultaneous drug-CDx launch in three APAC markets within 18 months of FDA approval.

Comparison of Regulatory Timelines

Country	Regulatory Authority	Avg Timeline	Clinical Data Requirements
Japan	PMDA / MHLW	9–15 months	Bridging or local trials
China	NMPA	18–24 months	Local trials usually required
South Korea	MFDS	12–18 months	Bridging possible
Australia	TGA	6–12 months	FDA/CE-based recognition
Singapore	HSA	6–9 months	Abridged review available

Conclusion

Approval of companion diagnostics in the Asia-Pacific region requires a strategic approach tailored to each country’s unique regulatory expectations. PMDA in Japan, NMPA in China, MFDS in South Korea, and TGA in Australia all have nuanced pathways for CDx co-approval. Global developers must plan ahead for bridging studies, labeling harmonization, and documentation localization. A regionally integrated strategy improves the likelihood of timely approvals and synchronized drug-CDx launches across key APAC markets.